Journal of Ovarian Research · Aug 18, 2026
Systemic immune-inflammation index in ovarian reserve, polyendocrine metabolic ovarian syndrome, and assisted reproductive technology outcomes: a narrative review
By Zhang B, Lai Z, Xu Y et al.
BACKGROUND: The systemic immune-inflammation index (SII) has emerged as a composite marker integrating platelet, neutrophil, and lymphocyte counts, reflecting both proinflammatory and immunoregulatory pathways. While increasing clinical evidence links the SII to ovarian reserve and assisted reproductive technology (ART) outcomes, a comprehensive synthesis of its clinical utility and underlying mechanisms is lacking. This narrative review summarizes the evidence linking the SII to anti-Müllerian hormone (AMH) levels, ovarian reserve, polyendocrine metabolic ovarian syndrome (PMOS), and ART outcomes, while proposing a unified "inflammation-oxidative stress-fibrosis" model for ovarian damage. KEY FINDINGS: Large cohort studies have demonstrated a robust negative correlation between the SII and the AMH/antral follicle count, independent of age and body mass index. In PMOS patients, the SII is associated with hyperandrogenism, insulin resistance, and dyslipidemia, and predicts embryo arrest and a reduced available embryo rate with clear threshold effects (SII > 733, log SII > 6.72). Mechanistically, an elevated SII reflects a dual imbalance: increased neutrophil‑platelet activation drives follicular inflammation and neutrophil extracellular trap formation (NETosis), while relative lymphopenia weakens immune tolerance at the maternal-fetal interface. This imbalance triggers oxidative stress and TGF‑β1‑mediated fibrosis, forming a vicious cycle of ovarian dysfunction and follicular atresia. Lifestyle and pharmacological interventions targeting this pathway, such as weight loss, metformin, and melatonin, show promise for improving fertility outcomes. CONCLUSION: The SII is a low‑cost, accessible marker with strong potential for risk stratification in fertility management. Prospective trials are needed to validate SII‑guided interventions.
doi.org/10.1186/s13048-026-02232-5Open accessPubMed 43035470Biomarkers